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LAM is a rare lung disease, found primarily in women of childbearing age, characterized by
cystic lung destruction and abdominal tumors (e.g., renal angiomyolipoma, lymphangioleio-
myoma). The disease results from proliferation of a neoplastic cell, termed the LAM cell, which
has mutations in either of the tuberous sclerosis complex (TSC) 1 or TSC2 genes. Molecular
phenotyping of LAM patients resulted in the identification of therapeutic targets for drug trials.
Loss of TSC gene function leads to activation of mammalian target of rapamycin (mTOR), and
thereby, effects on cell size and number. The involvement of mTOR in LAM pathogenesis is the
basis for initiation of therapeutic trials of mTOR inhibitors (e.g., sirolimus). Occurrence of LAM
essentially entirely in women is consistent with the hypothesis that anti-estrogen agents might
prevent disease progression (e.g., gonadotropin-releasing hormone analogues). Levels of
urinary matrix metalloproteinases (MMPs) were elevated in LAM patients, and MMPs were found
in LAM lung nodules. In part because of these observations, effects of doxycycline, an anti-
MMP, and anti-angiogenic agent, are under investigation. The metastatic properties of LAM301 496 1597; fax: þ1 301 496 2363.
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ª 2010 Published by Elsevier Ltd.Lymphangioleiomyomatosis (LAM) is a rare disease that
affects primarily women of childbearing age1e5 with an
incidence of approximately 2.6 per 1 million women.3
Organs involved in LAM include the lung, kidney (e.g.,
angiomyolipomas (AMLs)), and axial lymphatics (e.g., lym-
phangioleiomyomas, adenopathy).1e5 Patients with LAM
present most frequently with dyspnea and pneumo-
thorax1e5; other symptoms evident at presentation or
during the course of the disease include chylothorax,
hemoptysis, and ascites.1e3,5 Patients usually first notice
symptoms in their mid to late 30s,2e5 although diagnosis
may be delayed for 5e6 years, in part due to similarities of
the symptoms to those of more common lung diseases.
Survival rate 10 years after diagnosis was approximately
85%6 or 90%.7 The frequency of LAM is elevated among
patients with tuberous sclerosis complex (TSC), an inherited
disorder resulting from mutations in either the TSC1 or TSC2
genes. The clinical phenotype results from proliferation of
the neoplastic LAM cell, which contains the TSC mutation.
Characteristics of LAM
Pulmonary dysfunction
The characteristic pulmonary radiologic (computed
tomography (CT)) finding in patients with LAM is thin-walled
cysts spread diffusely throughout the lung parenchyma,
with no apical or basilar dominance.1,5,6,8 Cystic changes,
or the proliferation of LAM cells, are responsible for airflow
obstruction and decreased lung diffusion capacity. FEV1
(forced expiratory volume in one second) and DLco (diffu-
sion capacity of the lungs for carbon monoxide) are reduced
in approximately 60% of patients.8 Evidence of air-trapping
was observed on ventilation-perfusion scintigrams.2,9
Pathology
LAM results from the proliferation of abnormal smooth
muscle-like cells (LAM cells), neoplastic cells that contain
smooth muscle (a-smooth muscle actin (a-SMA)) and
melanoma cell (gp100) antigens10 as well as tuberous
sclerosis complex (TSC) gene mutations.11e13 Immunohis-
tochemistry revealed two morphological types of LAM cells:
epithelioid cells that react with HMB-45 (a monoclonal
antibody that recognizes a splice variant of pmel-17
(gp100)) and spindle-shaped cells reactive with antibodies
against proliferating cell nuclear antigen.14 LAM cells
proliferate in the vicinity of blood and lymphatic vessels,
near bronchioles, and in walls of the cystic lesions.10 In the
lung, LAM cell nodules in the lung are traversed by slit-like
lymphatic channels, whereas in extrapulmonary lesions,
LAM cells are seen in fascicles, which form plump rod-
shaped bundles separated by lymphatic channels.15 Lung
and lymphatic lesions and AMLs contain smooth muscle-likeLAM cells. AMLs differ, however, from other LAM lesions in
that they contain also underdeveloped vasculature and
adipose tissue.10,15e17 Hyperplastic type II pneumocytes are
seen in LAM lung nodules.18
Pathogenesis
TSC is an autosomal dominant disorder, characterized by
hamartomatous lesions, seizures, and mental retardation,19
resulting from mutations in the TSC1 or TSC2 genes, which
encode hamartin or tuberin, respectively.20 Approximately
one-third of women with TSC will present with pulmonary
cystic lesions radiographically and histologically identical to
those in LAM.21e23 TSC2 mutations are much more frequent
than those of TSC1 in sporadic LAM patients.11e13 In patients
with LAM, who have received a lung transplant, TSC muta-
tions identical to those present in the explanted lung were
observed in the donor lung, consistent with metastatic
properties of LAM cells.24,25 Similarly consistent with
a metastatic model of disease progression, LAM cells were
also isolated from blood, urine, and chyle of LAM patients.26
LAM natural history study
More than 500 patients with LAM, primarily from the United
States and Canada, but also from Europe and Southeast
Asia, were enrolled in the LAM natural history protocol
(NHLBI protocol 95-H-0186). In this longitudinal study, over
250 patients returned for five or more visits. Data on
survival and disease progression from X-ray, biopsy, and/or
physiological (e.g., pulmonary function tests) procedures
were generated and collated.5
Predictors of time to death or transplantation
LAM histology scores
Severity of lung involvement in LAM was assessed in
patients’ lung biopsies using the LAM Histology Score (LHS).
LHS is based on the extent of replacement of normal lung
tissue by cystic lesions and LAM cell infiltrates.27 The total
percentage of tissue involvement by these two histologic
patterns is graded as follows: LHS-1, <25%; LHS-2, 25% to
50%; and LHS-3, >50% of lung tissue involved. Using this
grading method, significant differences in survival and time
to transplantation for patients with LHS-1, -2, and -3 scores
were observed (Fig. 1). The ten-year survival was found to
be near 100% for LHS 1, 74.4% for LHS 2, and 52.3% for LHS
3.27 These data confirmed prior observations showing that
patients with more cystic disease have worse prognosis, and
are more likely to have lower DLco and more exercise-
induced hypoxemia than those with more muscular, solid
lesions.1 There was also a good correlation between DLco
and FEV1 and LHS
8 (Fig. 2).
Figure 1 KaplaneMeier survival curves of patients with
pulmonary lymphangioleiomyomatosis staged according to the
lymphangioleiomyomatosis histologic score (LHS). Patients
with LHS-1 have nearly 100% survival. Patients with LHS-3 have
the worst survival, and those with LHS-2 have an intermediate
survival (p< 0.002) (From reference 27).
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The severity of lung disease in LAM was graded semi-
quantitatively by computed tomography,9,28 according to
the percentage of the abnormal lung in three equal
pulmonary zones, represented by scans of three equal
portions of images, using the scale of: 0, absent; 1, less
than 30% abnormal; 2, 30%e60% abnormal; 3, more than
60% abnormal. Although good correlation of computed
tomography with lung function tests was demonstrated,
a predictive value of time to death or transplantation is not
yet shown.9,28
Quantitative grading CT scans correlated well with
measures of gas exchange and exercise performance.29,30
Recent advances in computed tomography make possible
the quantification of amount of lung parenchyma affected
by lung cysts.31 Percentage of cyst volume correlated with
expiratory flow (FEV1), residual volume and DLco.
30,31 The
value of this radiologic procedure for prediction of survival
or time to transplantation remains to be determined.Figure 2 Relationship between LHS and lung function at the
time of biopsy. Patients with an LHS of 2 (white bars) or 3 (gray
bars) have significantly lower DLCO than those with an LHS of 1
(black bars). Patients with an LHS of 2 (white bars) or 3 (gray
bars) also have lower FEV1 than patients with an LHS of 1 (From
reference 8).Pulmonary function tests
Pulmonary function testing is the simplest method of
assessing severity of lung disease in LAM.3,5,8,32 Abnormal-
ities of pulmonary function were seen in >60% of patients.
Both flow rates and lung diffusion can be normal, however,
in as many as one third of patients. Although most patients
have both airflow obstruction and impaired gas exchange,
some may have normal flow or only mild airflow obstruction
with a marked decrease in diffusion capacity. The severity
of lung disease in those patients should be graded by
assessment of gas exchange such as DLco, arterial blood
gases, or alveolar-arterial oxygen (A-a/O2) gradient. These
tests have limitations, however, as measurement of DLco is
difficult to standardize and has a large intra-individual
variability, whereas arterial blood gases at rest are very
frequently normal.
No prospective study has established the levels of FEV1
and DLco below which a LAM patient should be referred for
transplantation. As in other pulmonary diseases, lung
function criteria are only one component of the pre-
transplant evaluation, and despite severe functional
impairment, LAM patients can be relatively asymptomatic
at rest. In general, however, by the time LAM patients
undergo lung transplantation, they are on supplemental
oxygen and have percent-predicted FEV1 and/or DLco
below 30% of predicted.33 Still, even for patients in the last
group, survival rate without lung transplantation is not
possible to predict.Exercise testing
Exercise testing in LAM may demonstrate abnormalities of
gas exchange and/or ventilation and abnormal cardiovas-
cular function.33 Although lung function, especially DLco,
can reasonably predict peak oxygen uptake (VO2max),
VO2max is dependent on several additional factors, such as
skeletal muscle function and cardiovascular fitness.33,34
Exercise testing in LAM is important in that it elicits
abnormalities not readily apparent during resting lung
function, such as exercise-induced hypoxemia and pulmo-
nary hypertension.35 Because exercise-induced hypoxemia
occurs in patients with mild impairment in lung function,
cardiopulmonary exercise testing (CPET) or other types of
exercise testing (e.g., six-minute walk test (6MWT)) may be
useful measures of lung disease severity in LAM.30,33
An association between VO2max and LHS scores was
demonstrated, and patients with more severe LHS had
significantly lower VO2max.
33 Since LHS is a predictor of
death and time to transplantation, VO2max might also be
a useful predictor of survival in patients with LAM.
Good correlation between a quantitative CT severity
index and A-a/O2 gradient, dead space/tidal volume ratio,
and VO2maxwas reported.
29 Further, we found that VO2max,
DLco, and FEV1 correlated with the CT grade of disease
severity33 (Fig. 3). Moreover, good correlation between
quantitative scores of cystic-aerial lesions obtained from CT
scans and the 6MWT test have also been observed.30 This is
important because the 6MWT is a simple non-invasive test of
proven value in assessing disease severity of patients with
interstitial pulmonary fibrosis or pulmonary hypertension.36
Figure 3 Relationship between VO2max, FEV1, and DLCO and
CT grade of disease severity. Grade I, white bars; grade II,
black bars; grade III, cross-hatched bars (From reference 33).
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The rate at which lung function declines in LAM indicate
how aggressive the disease is and, in an individual patient,
has prognostic significance.32 In one study involving 36
patients, the rate of FEV1 decline was 118 21 ml/year and
for DLco was 0.905 0.26 ml/min/mmHg/year.37 Lazor
et al.38 reported an average decline in FEV1 of 106 35 ml/
year (3.4 0.8 % predicted) in 31 patients followed for
approximately five years. In a larger study of 275 patients
followed for approximately four years,32 the average yearly
rates of decline in FEV1 and DLco were 75 9 ml (1.7 0.4%
predicted), and 0.69 0.07 ml/min/mmHg (2.4 0.4%
predicted), respectively. Great variability in rates of
disease progression is reflected in the large standard devi-
ations. In some patients, LAM is a very aggressive disease
with declines of FEV1 or DLco from 5e10% predicted per
year. Hayashida et al.39 reported that in patients with FEV1
above one liter and DLco above 40% predicted, those
patients who presented with dyspnea (nZ 61), had
a median decrease in FEV1 of 285 ml (range 582.9 to
71.3 ml) per year and a median decrease in percent pre-
dicted DLco of 11.9% (range 20.7 to 3.2%). In patients
who presented with pneumothorax (nZ 74), loss of func-
tion was much slower with median annual decline in FEV1 of
16.7 ml (range 157.1 to þ46.8) or 1.6 % predicted (range
7.2 to þ6.4%). Thus, LAM lung disease can sometimes
progress quite slowly, taking decades to reach a level that
interferes with activities of daily living or requires contin-
uous oxygen therapy. In the absence of well-characterized
markers of severity of this disease, FEV1 and DLco (moni-
tored frequently) are now the best methods to assess
severity and progression of pulmonary disease in LAM.
Hormonal interventions
At present, no treatment is known to reverse effectively
the functional abnormalities and prevent ongoing lung
damage in LAM. Most systematically employed drug regi-
mens involved anti-estrogen therapy,5,32 based on the
understanding of LAM as a disease predominantly of pre-menopausal women that may worsen during preg-
nancy40e42 or following the administration of estro-
gens.43e48 Consequently, most women with LAM were
treated either with oophorectomy or long-term hormonal
therapy, or both. These treatments became a standard of
care, but no controlled studies evaluated their effective-
ness. Most publications included only a handful of patients
or were retrospective reviews. Taylor et al.49 reported no
improvement in 15 of 30 patients with LAM who had
undergone bilateral oophorectomy; 11 patients worsened,
and four were stable. The presence of estrogen or proges-
terone receptors in LAM lung lesions did not correlate with
therapeutic response. Gonadotrophin-releasing hormone
(GnRH) analogues were also found to be of benefit in the
treatment of LAM,50e52 although other studies were
inconclusive.53,54
In a retrospective study, Johnson and Tattersfield37
found that declines in FEV1 in patients treated with
progesterone were not significantly smaller than those in
untreated patients, although their initial levels of FEV1 and
DLco were lower, and rates of decline over three years
were not different. Decline in DLco was significantly less in
16 pre-menopausal patients treated with progesterone than
in 13 pre-menopausal untreated patients, but the two
groups were not matched. A decreased rate of functional
decline was reported in five patients for whom pre- and
post-treatment FEV1 and DLco data were available. Another
retrospective analysis of 275 patients32 revealed that
overall yearly rates of decline of FEV1 and DLco were not
significantly different in patients treated with oral or
intramuscular progesterone and patients who received no
progesterone after adjusting for differences in initial lung
function, age, and disease duration.
In sum, although LAM is primarily a disease of pre-
menopausal women, there is no clear evidence that treat-
ments aimed at removing or antagonizing the effects of
endogenous estrogens are effective.
Estradiol stimulated the growth of human angiomyoli-
poma TSC2/ cells32 and the pulmonary metastasis of
Tsc2/ Eker rat uterine leiomyoma-derived smooth muscle
cells (ELT3 cells) in mice.55 Enhancement by estrogens of
the survival and growth of intravenously injected Tsc2/
cells in mice55 was blocked by the MAPK/ERK kinase (MEK)
inhibitor CI-1040.55 Estrogen receptor activation in LAM
cells increased matrix metalloproteinase (MMP)-2 activity
promoting their invasiveness.56 Estrogens also accelerated
growth of angiomyolipoma cells in a xenograft tumor
model.57 All of these data suggest blockade of the MEK
pathway as a new potential approach to the treatment of
LAM. From these findings, anti-estrogen therapy may have
a role in the treatment LAM, but precluding LAM cell
metastasis could be crucial for its safety and/or
effectiveness.Association of modifier genes and biomarkers
with disease severity and progression in LAM
Biomarkers linked to diverse LAM cell functions or disease
characteristics could be useful as surrogates to follow
disease progression and/or responses to therapy. There-
fore, the discovery of modifier genes and biomarkers that
Targeted therapies for lymphangioleiomyomatosis (LAM) S49are closely associated with clinical phenotypes of LAM is an
important goal of LAM research.
Extracellular matrix proteins and pneumothoraces
Pneumothorax is one of the most frequent presentations of
patients with LAM,5 with a rate of recurrence surpassing
that in any other pulmonary disease.5,58 In a study of 227
patients with LAM,59 the prevalence of pneumothorax was
related to progression and severity of disease. Pulmonary
function testing, CT grade, and cyst size of patients with
LAM were compared to a history of pneumothoraces. Cyst
size was graded by the average cyst diameter measured on
high-resolution computed tomography (HRCT) using the
following scale: size I< 0.5 cm; size II 0.5e1.0 cm; and size
III> 1.0 cm. Patients with a history of pneumothorax were
more likely to have larger cysts than those without. Multi-
variate analysis of a subgroup of LAM patients with mild
disease and CT grade I revealed that FEV1 declined more
rapidly among those with a history of pneumothorax than
those who did not, suggesting that early disease progression
may be related to the occurrence of pneumothoraces.59
Collagens I and III are principal components of the
alveolar wall scaffolding in the lung parenchyma.60 Matrix
metalloproteinase (MMP)-1 in LAM lung nodule is capable of
degrading collagen and elastin.61e63 It was hypothesized
that the occurrence of pneumothoraces might be related to
differences in genes involved in extracellular matrix
formation or function.59 Patients with LAM were genotyped
for polymorphisms in collagens I and III and MMP-1 to
associate with susceptibility to LAM or the occurrence of
pneumothorax. No correlation of polymorphisms with
susceptibility to LAM was found, but patients with and
without pneumothoraces differed in frequencies of poly-
morphisms in types I and III collagen and MMP-1 genes. An
association of collagen III polymorphism with cyst size,
although only a trend, was suggestive of a relationship
between cyst size, type III collagen, and pneumothorax.
Types I and III collagen and MMP-1 might be modifier genes
affecting changes in the extracellular matrix that result in
a greater susceptibility to pneumothorax and rate of
decline in lung function.59
Lymphatic involvement in LAM
Lymphatic involvement in LAM includes lymphangioleio-
myomas, adenopathy, and chylous pleural effusions.
Adenopathy on CT scans appears as round and/or elliptical,
well-circumscribed solid masses with replacement of
normal tissue by smooth muscle (LAM) cells.64 Avila et al.64
reported a 39% frequency of adenopathy in patients with
LAM. Patients with abdominal adenopathy were more likely
to have severe disease by CT grade.
Lymphangioleiomyomas, which occur in ca. 16%e21%64,65
of patients with LAM, appear on CT scans as thin or thick-
walled encapsulated lobulated masses containing LAM
cells, which can be seen microscopically infiltrating the
adipose tissue surrounding the fibrous capsule of the
lesion.15,64 Cysts contained fluid components. Lym-
phangioleiomyomas are thought to result from the prolif-
eration of LAM cells, causing obstruction and subsequentdilatation of lymphatic vessels. Chylous ascites may occur
from the rupture of distended lymphangioleiomyoma cysts.
Lymphangioleiomyomas are usually found in conjunction
with enlarged abdominal lymph nodes, pleural effusions,
ascites, and dilatation of the thoracic duct.64 In two
radiologic studies, using sonography and/or CT scans,65,66
12 of 13 and 21 of 22 patients with LAM demonstrated
diurnal size changes in lymphangioleiomyomas. Observation
of these changes on CT or sonography is helpful in the
differential diagnosis of lymphangioleiomyomas and in the
exclusion of lymphomas and other solid lymphatic masses
that do not exhibit diurnal variation in size.
The identification of relatively specific lymphatic endo-
thelial markers has facilitated analysis of the patho-
physiologic role of lymphatic involvement in LAM. Exam-
ples are VEGFR-3 (FLT-4), a FMS-like tyrosine kinase 4 gene
and a mediator of lymphangiogenesis67; VEGF-C and VEGF-
D, both lymphatic growth factor ligands for VEGF-R368,69;
podoplanin, a glomerular podocyte membrane mucoprotein
recognized by antibody D2-40; and PROX-1, a transcription
factor required for the differentiation of lymphatic endo-
thelial cells.69,70
Immunohistochemical and immunocytochemical studies
using specific lymphatic and vascular endothelial markers
(e.g., CD31/PECAM, a platelet endothelial cell adhesion
molecule and marker for vascular endothelial cells), as well
as antibodies against HMB-45 and a-smooth muscle actin
(LAM cell markers), demonstrated the extensive lymphatic
involvement characteristic of LAM in the lungs and
extrapulmonary tissue, including lymph nodes, uterus, and
ovaries.71 LAM cells proliferated in the axial lymphatics,
particularly the retroperitoneal area, including the dia-
phragm, thoracic duct, and left jugulosubclavian junc-
tion.71,72 Anti-VEGFR-3 antibody reactivity of cells in the
lining of the slit-like spaces within the LAM foci or nodules
confirmed these structures as lymphatic tracts. Further,
cells reactive with anti-VEGFR-3 antibodies, in mediastinal
or retroperitoneal lymph nodes, appeared to segregate LAM
cells into nodular or cluster-like arrangements. It was
concluded that the observance of anti-VEGFR-3 reactive
cells associated with LAM lung lesions indicated an active
lymphangiogenic process linked to LAM. Consistent with
these findings, microscopic observations revealed parts of
LAM foci extending into the lymphatic lumen and clusters of
LAM cells in lymphatic vessels.72 These LAM cell clusters
(LCCs) were characterized as having an inner core of
spindle-shaped cells, immunoreactive for anti-HMB-45, and
an outer, single layer of flattened cells that react with anti-
VEGFR-3 antibodies. LCCs were observed in chylous pleural
and peritoneal effusions, and cystic lymphangioleiomyo-
mas, as well as in the lung and in lymphatic channels in fat
tissues surrounding lymph nodes containing LAM cells.72
Based on these results, it was proposed that the shedding
of LCCs by lymphangiogenesis-mediated fragmentation of
LAM lesions, and their subsequent entry into the lymphatic
circulation was a mechanism for the dissemination of LAM
cells.
Immunoreactive VEGF-C and VEGF-D are both present in
LAM cells.71,73 Serum levels of VEGF-C and VEGF-D quanti-
fied by enzyme-linked immunosorbent assay (ELISA) in 44
patients with sporadic LAM were compared to serum levels
in 24 healthy volunteers. Serum of VEGF-C in patients with
S50 C.G. Glasgow et al.LAM was significantly lower than that in healthy volun-
teers.73 In two separate studies,73,74 serum VEGF-D levels
were significantly higher in LAM patients than in controls
(Fig. 4A). The higher levels of VEGF-D correlated with more
severe disease (CT grade),74 and worse FEV1/FVC ratio,
DLco (adjusted for lung volune),73 and percent-predicted
DLco,74 all consistent with a role for VEGF-D as a growth
factor related to lymphangiogenesis in LAM.
When encountering a patient with pulmonary LAM in the
absence of extrapulmonary manifestations (such as AMLs),
distinguishing LAM from other cystic diseases can be prob-
lematical without performing a biopsy. Young et al.75
measured serum levels of VEGF-D in 38 LAM patients, 24
healthy controls, and 27 patients with other pulmonary
diseases (Langerhans-cell histiocytosis, lymphangiomatosis,
and emphysema). Serum levels of VEGF-D in patients with
LAM were significantly higher (as much as 30 times) thanFigure 4 Serum Levels of VEGF-D in Lymphangioleiomyo-
matosis. In Panel A, serum VEGF-D levels in all patients with
sporadic lymphangioleiomyomatosis (LAM) (nZ 111) were
compared to those of healthy volunteers (nZ 40). Panel B
shows patient samples compared on the basis of thoracic or
abdominal lymphatic involvement (presence (nZ 77) or
absence (nZ 34) of lymphangioleiomyomas and/or adenop-
athy) and the presence (nZ 40) or absence (nZ 71) of renal
angiomyolipomas (AMLs). All groups were compared to healthy
volunteers (nZ 40). (þ)Z presence of, ()Z absence of.
Each A represents serum measurement of VEGF-D from one
patient or healthy volunteer. Lines represent mean values
(From reference 74).those in the other groups. Based on these results, serum
VEGF-Dmight seem a potential biomarker for LAM. In a study
of a larger cohort of patients with LAM (LAM nZ 111; healthy
volunteers nZ 40),74 however, statistic significance of the
difference in serumVEGF-D levels of LAM versus controls was
not maintained when the LAM population was divided into 2
groups based on lymphatic involvement (Fig. 4B). Serum
VEGF-D remained significantly different only when normals
were compared to LAMpatientswith lymphatic involvement,
not when compared to patientswith only pulmonary disease,
regardless of the presence or absence of AMLs. Conse-
quently, low serumVEGF-D levelsmay reflect confinement of
the disease to the lung. Results of the lymphatic growth
factor studies indicate that lymphatic involvement may
occur with disease progression and that levels of VEGF-D
likely reflect lymphatic involvement in LAM, but may not
be useful for the diagnosis of LAM in patients who have only
cystic disease. Given these data, we suggest that clinical
therapies targeted at VEGF-D and/or VEGFR-3 may slow
lymphatic proliferation in LAM and possibly disease
progression. Potential therapies include amousemonoclonal
antibody (VD1) that competes with mature VEGF-D for
binding to VEGFR-2 and VEGFR-3, thereby inhibiting its
function.76 In a mouse tumor model, VD1 inhibited VEGF-
D-induced formation of lymphatics and tumor growth.
Development of a human version of this antibody is in prog-
ress,69,77 and other drugs targeting the VEGFR-3 pathway
(e.g., AZD2171, sorafenib, sunitinib) are in clinical trials.78
Metastasis and LAM
LAM is characterized by the proliferation of smooth muscle-
like cells that are disseminated in blood, urine, and chylous
effusions26 and may be able to form lung metastases.79 In
other types of cancer, the multistep metastatic process or
“invasion-metastatic cascade” starts with a primary
neoplasm that undergoes progressive growth followed by
vascularization, invasion, detachment, embolization, cell
survival in the circulation, arrest, extravasation, evasion of
host defenses and growth at metastatic sites.80 Since all of
these steps are critical, blocking any of them could block
the metastatic process, which involves “crosstalk” between
the metastatic cell and its microenvironment.
The CD44 gene in chromosome 11 encodes 20 exons that
undergo complex splicing to yield at least 10 different
splice variants.81 The multiple interactions of CD44 proteins
suggest its participation in cell binding to extracellular
matrix, endothelial cells, and other cells in the neoplasm
microenvironment.82 The metabolism and processing of
CD44 presents interesting options for targeting. Splicing
factors Sam68 and SRm160, which are activated by the Ras/
MAPK pathway, regulate expression of CD44 forms83e85 and
Ras activation appears to be regulated by CD44v6.83 Further
investigation into the RAS/MAPK pathway downstream
effects on CD44 splicing factors may elucidate therapeutic
targets for controlling metastasis of LAM cells.
Osteopontin, an acidic 32.5-kDa phosphocytokine that is
upregulated by TGF-b,86 EGF,87 and progesterone,88 not
only binds CD44,89 but also regulates its splicing.90 Oste-
pontin has been correlated with several metastatic
processes and CD44v6 expression. The finding of elevated
osteopontin levels in serum of patients with pulmonary
Targeted therapies for lymphangioleiomyomatosis (LAM) S51LAM,91 suggested that blocking its production could inter-
fere with disease progression. Amounts of cleaved CD44
forms have been correlated with disease progression, and
metalloproteases92 and ADAM1093 cleave CD44 to modulate
cell attachment to extracellular matrix. Modification of
CD44 enzymatic cleavage as well as of its splicing and
turnover could involve several potential therapeutic
targets.
Expression of the CD44v6, a splice variant of CD44, was
detected in squamous cell carcinoma (head and neck,
esophagus, lung, skin, cervix, vulva), adenocarcinoma
(breast, Barrett’s esophagus, lung, gastric, pancreas,
colon/rectum endometrium, prostate) and other tumors
(thyroid carcinoma, small cell lung cancer, renal cell
carcinoma, urinary bladder, ovarian cancer and basal
carcinoma).82 The presence of CD44v6 in so many cancers
spurred researchers to target the molecule94 using anti-
sense technologies, antibodies (U36, chU36, BIWA 4),95,96
and peptides (patent JP 2006083122). The anti-CD44 anti-
body H90 was notably successful in eradicating acute
myeloid leukemia.97 As most approaches were directed at
the primary tumor, very little was done to target the actual
metastatic cells. CD44v6 is found in LAM lesions that have
TSC2 loss of heterozygosity, as well as in cultured cells
grown from LAM lungs, similar to observations in other
metastatic cells.91 Presence of the CD44v6 splice variant on
circulating LAM cells means that interference with its
specific interactions could prevent anchoring of the cell to
a metastatic site.
Cancer cells, regulated by the interaction of chemokines
and their receptors, localize to sites of metastasis. Produc-
tion of chemoattractants mainly at the metastatic site was
shown for breast cancer and melanoma cells.98 The meta-
static cells display a defined group of receptors that are
activated by chemokines produced by the normal stromal
cells. LAM cells with identical mutations have been found in
both lung and kidney of the same individual,11 consistent
withmetastasis, but the sites of origin were not determined.
We have observed that LAM cells within the lung lesions
reacted with antibodies raised against CCR2, CXCR4, CCR7,
or CCR1, and cells that were selectively mobilized by CCL2 /
MCP1 showed loss of heterozygosity at the TSC2 locus.99 In
addition, tuberin appeared to alter CCL2 expression.100
These findings have led to the proposal of a positive feed-
back of selective chemoattraction. Multiple drugs that
target CCR2101 are known. We speculate that blocking the
CCL2/CCR2 interaction via drug therapy might prevent
metastasis of LAM cells and, therefore, disease progression.
Multiple approaches, including the use of truncated MCP-1,
anti-MCP-1 and aptamers, have been used to inhibit the
function of CCL2.102,103
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are zinc-dependent
endopeptidases critical in physiological embryogenesis and
tissue remodeling. Dissociation of the cysteine-zinc complex
produces an active zymogen capable of degrading extracel-
lular matrix substrates.104 This activation is inhibited by
endogenous tissue inhibitors of metalloproteinases
(TIMPs).104 MMP-9 and MMP-2 are able to degrade a variety of
matrix substrates including gelatin, collagen I, collagen IV,laminin, and elastin.104 MMP activity is believed to facilitate
tumor cell invasion by disrupting basement membranes.105
Concentrations of MMP-9 (in serum/plasma, and protein
activity) have consistently correlated with the presence of
cancer106,107 or metastasis108,109 and disease progres-
sion.110,111 Levels of MMP-2 and MMP-9 activity in urine were
predictive of disease status in a variety of cancers.112
Degradation of elastic fibers in areas of smooth muscle
proliferation was found in light and electron microscopic
immunohistochemical observations of LAM lung biopsy
specimens.61 In agreement, immunohistochemical analysis
of LAM tissue from lung biopsies indicated greater reactivity
of MMP-2 and MMP-9, but not of TIMP-1 and TIMP-2, in LAM
cells than in normal lung tissue.62 MMP-2 and type IV collagen
colocalized in some LAM cells.62 In another study63 MT1-MMP,
an activator of MMP-1, was associated with proliferating LAM
cells, all suggesting from these studies a role for metal-
loproteinases in the cystic lung destruction of LAM. Because
doxycycline is a MMP inhibitor that affects growth and
migration of neoplastic cells, angiogenesis, lymphangio-
genesis, and smooth muscle cell growth,113,114 MMP-9 and
MMP-2 were proposed as biomarkers to measure disease
progression during doxycycline therapy in a patient with
LAM.115 Levels of MMP-2, MMP-9, and MMP-9 complexed with
neutrophil gelatinase-associated lipocalin (NGAL), which
inhibits MMP-9 degradation,116 were elevated before initia-
tion of doxycycline treatment. After seven months of
treatment with doxycycline, patient lung function had
improved and MMP levels had decreased.115
Cyclin-dependent kinase 2 (CDK2) inhibitors
CDK2 inhibitors are potentially another therapeutic option
for LAM.117 Tuberin is a negative regulator of cell cycle
progression that shortens the G1 phase of the cell cycle by
binding p27KIP1, a cyclin-dependent kinase inhibitor, pre-
venting its degradation and leading to inhibition of the cell
cycle. In the absence of tuberin, p27 is mislocalized in the
cytoplasm, allowing progression of the cell cycle.118e121
Tuberin prevented degradation of p27, a major regulator
of cell cycle progression, increasing the amount of p27
bound to CDK2. CDK2 inhibitors such as roscovitine, a new
potential anti-cancer therapy,122 may have a role in the
therapy of LAM.
Regulation of TSC1- and TSC2-dependent
pathways in LAM cells by mTOR
In LAM cells, mutations in the TSC2 or TSC1 genes resulted
in defective regulation of a key protein kinase, mTOR.
Further investigations of TSC1- and TSC2-dependent signal
transduction pathways have led to promising pharmaco-
logical targets. mTOR (mammalian target of rapamycin) is
an intracellular serine/threonine kinase that is responsible
for mediating signals of energy availability and growth
factor stimulation to regulate cell growth and metabolism
(Fig. 5). Two different complexes contain mTOR: mTORC1,
comprising mTOR, mLST8 (mammalian lethal with SEC13
protein 8), and raptor (regulatory associated protein of
TOR); and mTORC2, containing mTOR, mLST8, rictor
(rapamycin-insensitive companion of TOR), mSIN1
Figure 5 mTOR dependent pathways. Two different complexes contain mTOR: mTORC1, which is acutely sensitive to rapamycin,
and mTORC2, which is inhibited by rapamycin (in italics) after prolonged exposure. Activation of mTORC1 leads to protein
translation, and thereby cell growth and proliferation, while activation of mTORC2 results in the phosphorylation of Akt. Growth
factors, hypoxia, and energy stress affect the status of the TSC1/2 complex, leading to inactivation of the tumor suppressor
complex in the presence of growth factors and activation in the presence of stress. TSC1/2 inhibits mTORC1 through its Rheb-GAP
activity: Rheb-GTP is necessary for the activation of mTORC1, preventing the interaction of MTOR with its endogenous inhibitor
FKBP38. The presence of amino acids stimulates the localization of mTORC1 in Rheb-containing compartments through the actions
of Rag-GTPases. mTORC1 is also involved in a negative feedback loop, which blocks growth factor- stimulated phosphorylation of
Akt. TSC1/2 activates mTORC2, which then phosphorylates Akt.
S52 C.G. Glasgow et al.(mammalian stress-activated-protein-kinase-interacting
protein 1), and PRR5 (proline-rich protein 5).123e125 The
substrate specificity of mTORC1 is determined by raptor.126
mTORC1 is acutely sensitive to rapamycin, whereas
mTORC2 is sensitive only to prolonged rapamycin
treatment.127,128
TSC1 and TSC2 form a cytoplasmic complex129e131 that
acts upstream of mTOR to integrate growth factor, energy,
and stress signals and thereby regulate protein synthesis
and cell growth and proliferation. TSC1, on chromosome
9q34,132 encodes the ca. 130-kDa protein hamartin, which
regulates levels of Rho-GTP. It interacts with proteins of the
ezrin-radixin-moezin family and with tuberin, the TSC2
protein,130,133e135 encoded by TSC2 on chromosome
16p13.3.136 The 198-kDa tuberin protein molecule contains
a region with significant similarity to GTPase-activating
proteins and a region that binds hamartin,130,133,137e139
which stabilizes it and prevents its ubiquitin-mediated
degradation.140
The TSC1/2 complex is a negative regulator of mTORC1.
TSC2 is a GAP (GTPase-activating protein) for the GTPase
Rheb (Ras homolog enriched in brain), that accelerates its
Rheb conversion from the active Rheb-GTP to an inactive
Rheb-GDP.137e139 Rheb-GTP activates mTORC1, resulting in
phosphorylation of substrates such as ribosomal S6 kinases,
e.g., S6K1, and eukaryotic initiation factor 4E-binding
proteins, e.g., 4E-BP1.141 These phosphorylations lead to S6kinase activation and 4E-BP inhibition, resulting in
enhanced translation of 50 TOP (terminal oligopyrimidine
tract)-containing RNAs and cap-dependent translation. In
response to growth factors, Akt phosphorylates and inac-
tivates TSC2,142,143 which relieves the TSC1/2 inhibition of
Rheb, allowing mTORC1 activation and promoting trans-
lation.144e146 Under poor growth conditions, FKBP38 binds
mTORC1 and inhibits its activity.147 Rheb-GTP enables
activation of mTORC1 by preventing the interaction of
FKBP38 and mTOR.147 Phosphorylation of TSC2 by Akt may
lead to its binding of 14-3-3 and its resulting inactivation.148
Growth factors cannot stimulate mTORC1 without
a supply of amino acids or cellular energy (in the form of
ATP) sufficient to fuel translation. Under conditions of
energy stress as detected by increased intracellular levels
of AMP, activated AMPK (AMP-dependent protein kinase)
phosphorylates TSC2.149 This phosphorylation activates
TSC2149 and thereby inhibits mTORC1. Hypoxia also causes
AMPK activation, as oxygen is required for aerobic mito-
chondrial production of ATP by oxidative phosphorylation.
Hypoxia stimulates HIFa (hypoxia-inducible factor a), which
increases transcription of REDD1 that binds 14-3-3 proteins
and can facilitate dissociation of Akt-induced TSC2/14-3-3
complexes, thereby activating TSC2 and inhibiting
mTORC1.148
Ample supply of amino acids is needed also to permit
localization of mTORC1 correctly for activation by Rheb.
Targeted therapies for lymphangioleiomyomatosis (LAM) S53Amino acids stimulate GTP binding by Rag (Ras-related
small GTP-binding protein)-GTPase heterodimers, which
are able to bind raptor, and result in localization of
mTORC1 in compartments where Rheb is able to activate
mTORC1.150 This translocation of mTORC1 stimulated by
amino acids allows the mTORC1 activation and mRNA
translation only when substrate sufficient for translation is
present.
The TSC1/2 complex is a positive regulator of mTORC2,
resulting in phosphorylation of Akt.151,152 TSC1/2 physically
interacts with mTORC2, and levels of TSC2 expression are
correlated with increases in Akt phosphorylation.151 Loss of
TSC1/2 in disease leads to an inability to activate Akt,
through both the inactivation of mTORC2 and through
a negative feedback loop created by activated mTORC1,
which blocks growth factor-stimulated phosphorylation of
Akt.123,151 As Akt is an important kinase in tumor progres-
sion, an inability to activate Akt may result in a more
“benign” disease such as TSC, where activation of mTORC1
may initially result in tumor formation, but the negative
feedback loop on Akt phosphorylation and inactivation of
mTORC2 may limit disease progression.151
Rapamycin was approved in 1997 for immunosuppression
in kidney transplant patients, and in 2003 for use in
cardiovascular stents to prevent smooth muscle cell prolif-
eration.153 Rapamycin and FKBP-12 (FK506 binding protein-
12) forms a complex that binds and inhibits mTORC1.154
mTORC1 responds acutely to rapamycin, whereas pro-
longed rapamycin treatment can inhibit mTORC2. The
differences in sensitivity have been proposed to be due to
phospholipase D (PLD) action and the phosphatidic acid (PA)
product.155,156 PLD activity generating PA from phosphati-
dylcholine hydrolysis was elevated in human cancer cell
lines.157e159 PA, which is required for the formation/stabi-
lization of mTOR complexes, binds the FKBP12-rapamycin
domain, competing with rapamycin for FKBP12 binding.160
It was proposed that the apparent differences in sensi-
tivity of the two mTOR complexes reflect a difference in the
affinities for PA, such that mTORC2/PA is a more stable
complex than mTORC1/PA, rendering mTORC1 more sensi-
tive to rapamycin and requiring a more prolonged treatment
with rapamycin to inhibit mTORC2.155,156
Effects of rapamycin or sirolimus have been investigated
on tumors or renal cysts in mouse and rat models of TSC.
CCI-779 (temsirolimus, a rapamycin analog) reduced the
number of cystadenomas per kidney in Tsc2þ/ mice.161
Rapamycin treatment of the Eker rat, which carries
a germline mutation of Tsc2 that is functionally null,
diminished tumors of the kidney and suppressed phos-
phorylation of S6 and 4E-BP1.162 There were, however, rare
persistent renal tumors with hyperphosphorylated S6
proteins after rapamycin treatment, consistent with resis-
tance to rapamycin.
Several ongoing clinical trials are assessing the effect of
rapamycin or its analogs on AML size in TSC and/or LAM
patients. Some of the trials evaluate also effects on
pulmonary function in LAM patients. A 24-month non-
randomized study163 of TSC and/or LAM patients examined
the effects of 12 months of sirolimus on AML volume and
pulmonary function (in the LAM patients), and then fol-
lowed the patients another 12 months without drug. AML
volume was smaller at 12 months (53% of baseline),whereas, without sirolimus, the AMLs were 86% larger (86%
at 24 months). Some improvement in airflow and gas trap-
ping was found in LAM patients although there was no
effect on DLCO. Whereas the effects of sirolimus tended not
to be permanent, improvements in spirometry of some LAM
patients persisted after treatment stopped. Information
about clinical trials of rapamycin and its analogs on disease
progression in TSC and LAM patients can be found at www.
clinicaltrials.gov.
Conclusion
The discovery of an effective treatment for LAM is thus far
elusive. Data from a longitudinal natural history study
defined predictors of time to transplantation or death and
identified extra-pulmonary manifestations of LAM. Molec-
ular insights and the discovery of possible biomarkers in
LAM have led to potential therapeutic options and means to
monitor effects of therapy. Detection of estrogen receptors
in LAM lesions and differences in post- and pre-menopausal
disease progression suggest that hormonal intervention may
offer benefits, and further study is warranted to establish
the effectiveness of specific interventions. The isolation of
LAM cells from blood and other body fluids offers a possible
non-invasive diagnostic tool. VEGF-D may be a marker for
lymphatic involvement in LAM and anti-VEGF-D therapies
may slow lymphatic proliferation in LAM. Elevation of MMP-
2/MMP-9 levels suggests doxycycline as a useful treatment,
and CD44v6 may represent an effective target for cytotoxic
agents. Elucidation of the effects of TSC gene mutations on
the mTOR pathway has led to a clinical trial using sirolimus.
The use of pharmacological agents against these
molecular targets has advantages as well as raising ques-
tions. Side effects of anti-estrogen therapy, such as loss of
bone mineral density, may preclude the use in most
patients of those presently available. MMP inhibitors, that
are not selective for a particular enzyme, may produce off-
target effects. The effectiveness of any treatment may
depend on disease stage or many other physiological vari-
ables for each individual. All of these factors should be
considered in designing treatment studies.Acknowledgments
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